European Stocks Close Lower; Bank Stocks Among Notable Losers

European stocks closed lower on Friday with investors assessing monetary policy decisions of several central banks, and digesting a slew of European and U.S. economic data. Eurozone business recovery slowed sharply in June as the manufacturing sector downturn gathered momentum and activity in the services sector deteriorated. The HCOB\'s preliminary composite Purchasing Managers\' Index, compiled...

Read More

Swiss Market Ends Notably Lower

The Switzerland market ended notably lower on Friday with stocks reeling under pressure right through the day\'s session amid concerns about the outlook for global economic growth. The benchmark SMI ended down by 115.29 points or 0.95% at 12,012.87. The index touched a high of 12,110.54 and a low of 11,987.23 in the session. Holcim...

Read More

TSX Ends Marginally Down

The Canadian market ended marginally down on Friday after moving in a very narrow range below the flat line, as investors remained reluctant to pick up stocks amid a lack of significant triggers. The benchmark S&P/TSX Composite Index ended down by 26.49 points or 0.12% at 21,554.86. The index moved between 21,499.57 and 21,586.39. The...

Read More

Boston Scientific To Acquire Silk Road Medical For $27.50/share In Deal Valued At About $1.16 Bln

Medical device company Boston Scientific Corp. (BSX) announced Tuesday it has entered into a definitive agreement to acquire smaller peer Silk Road Medical, Inc. (SILK) for $27.50 per share, reflecting an enterprise value of approximately $1.16 billion. Boston Scientific has developed an innovative platform of products to prevent stroke in patients with carotid artery disease...

Read More

Bay Street Likely To See Muted Start

Canadian shares are likely to open on a muted note Tuesday morning, as investors await some crucial economic data from the U.S., and comments from several Fed officials for clues about the interest rate trajectory. Movements are likely to remain somewhat rangebound in lackluster trade. The Canadian market ended weak on Monday, losing for a...

Read More

Intra-Cellular Says Phase3 Trial Study 502 Of Lumateperone In MDD Meets Primary Endpoint

Biopharmaceutical company Intra-Cellular Therapies, Inc. (ITCI) announced Tuesday positive topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder (MDD). This trial, in conjunction with the previously reported positive Phase 3 study, Study 501, forms the basis for lumateperone sNDA for the adjunctive...

Read More